Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
13
BRTX Quote, Financials, Valuation and Earnings
Last price:
$1.11
Seasonality move
:
-2.73%
Day range:
$1.08 - $1.15
52-week range:
$0.98 - $2.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
23.77x
P/B ratio:
4.45x
Volume:
24.9K
Avg. volume:
64.1K
1-year change:
-24.66%
Market cap:
$9.8M
Revenue:
$401K
EPS (TTM):
-$1.51
Analysts' Opinion
-
Consensus RatingBioRestorative Therapies, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.00, BioRestorative Therapies, Inc. has an estimated upside of 1081.82% from its current price of $1.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $1.10.
Fair Value
-
According to the consensus of 1 analyst, BioRestorative Therapies, Inc. has 1081.82% upside to fair value with a price target of $13.00 per share.
BRTX vs. S&P 500
-
Over the past 5 trading days, BioRestorative Therapies, Inc. has underperformed the S&P 500 by -1.14% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
BioRestorative Therapies, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioRestorative Therapies, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter BioRestorative Therapies, Inc. reported revenues of $11.8K.
Earnings Growth
-
BioRestorative Therapies, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter BioRestorative Therapies, Inc. reported earnings per share of -$0.33.
Enterprise value:
5.3M
EV / Invested capital:
2.40x
Price / LTM sales:
23.77x
EV / EBIT:
--
EV / Revenue:
13.79x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-0.49x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$150.3K
Return On Assets:
-123.4%
Net Income Margin (TTM):
-3304.77%
Return On Equity:
-199.72%
Return On Invested Capital:
-199.46%
Operating Margin:
-31432.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $130.2K | $377K | $383.4K | $233.6K | $11.8K | |
| Gross Profit | -$97.7K | $170.9K | $150.3K | $167.1K | -$51.4K | |
| Operating Income | -$16.7M | -$12.1M | -$14.5M | -$2.3M | -$3.7M | |
| EBITDA | -$16.5M | -$11.9M | -$14.3M | -$2.2M | -$3.7M | |
| Diluted EPS | -$4.20 | -$0.71 | -$1.51 | -$0.13 | -$0.33 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.2M | $16.9M | $12.6M | $13.5M | $4.7M | |
| Total Assets | $2.2M | $17.9M | $13.8M | $14.6M | $5.6M | |
| Current Liabilities | $873.5K | $717.2K | $932.6K | $4.6M | $3.4M | |
| Total Liabilities | $7.1M | $915.9K | $975K | $4.6M | $3.4M | |
| Total Equity | -$4.9M | $17M | $12.8M | $10M | $2.2M | |
| Total Debt | $6.2M | $198.7K | $42.4K | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$6.4M | -$7.5M | -$10.7M | -$1.7M | -$2.9M | |
| Cash From Investing | $13.7K | -$1.1M | $8M | $936.8K | $2M | |
| Cash From Financing | $2.3M | $7.6M | $1.8M | -- | -$49.3K | |
| Free Cash Flow | -$6.7M | -$7.6M | -$10.8M | -$1.8M | -$2.9M | |
BRTX
Sector
Market Cap
$9.8M
$28.7M
Price % of 52-Week High
43.14%
51.38%
Dividend Yield
0%
0%
Shareholder Yield
-16.98%
-1.4%
1-Year Price Total Return
-24.66%
-21.4%
Beta (5-Year)
0.082
0.519
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.09
200-day SMA
Sell
Level
$1.58
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$1.14
Relative Strength Index (RSI14)
Sell
Level
40.04
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-37.6547
50-day SMA
Sell
Level
$1.38
MACD (12, 26)
Sell
Level
-0.09
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-18.5124)
Sell
CA Score
(Annual)
Level (-3.5154)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (6.5281)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company's initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.
Stock Forecast FAQ
In the current month, BRTX has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BRTX average analyst price target in the past 3 months is $13.00.
-
Where Will BioRestorative Therapies, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioRestorative Therapies, Inc. share price will rise to $13.00 per share over the next 12 months.
-
What Do Analysts Say About BioRestorative Therapies, Inc.?
Analysts are divided on their view about BioRestorative Therapies, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioRestorative Therapies, Inc. is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is BioRestorative Therapies, Inc.'s Price Target?
The price target for BioRestorative Therapies, Inc. over the next 1-year time period is forecast to be $13.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BRTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioRestorative Therapies, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of BRTX?
You can purchase shares of BioRestorative Therapies, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioRestorative Therapies, Inc. shares.
-
What Is The BioRestorative Therapies, Inc. Share Price Today?
BioRestorative Therapies, Inc. was last trading at $1.11 per share. This represents the most recent stock quote for BioRestorative Therapies, Inc.. Yesterday, BioRestorative Therapies, Inc. closed at $1.10 per share.
-
How To Buy BioRestorative Therapies, Inc. Stock Online?
In order to purchase BioRestorative Therapies, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BRTX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BRTX
Sector
P/E ratio
--
23.97x
PEG ratio
-0.01x
-0.01x
P/B ratio
4.45x
1.83x
Price / LTM sales
23.77x
1.60x
Growth Metrics
BRTX
Sector
Revenue growth
-94.95%
4.8%
Earnings growth
-147.99%
11.11%
Revenue (5-year growth)
25.27%
6.45%
Earnings forecast
-$0.38
-$0.20
Profitability
BRTX
Sector
Profitability FY 2024
$183.9K
$3.5M
Return on invested capital
-199.46%
-31.16%
Return on assets
-123.4%
-27.72%
Return on equity
-199.72%
-37.13%
Earnings Date
Last Earnings Date
Dec
12
Next Earnings Date
Dec
12
Estimated Next Earnings Date
Mar
13
Balance Sheet
BRTX
Sector
Total cash
$4.5M
$27.2M
Short term investments
$10.2M
$26M
Total assets
$12.3M
$79.7M
Long term debt
--
$3.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
61
PLAB alert for Dec 11
Photronics, Inc. [PLAB] is up 6.18% over the past day.
Buy
77
DHIL alert for Dec 12
Diamond Hill Investment Group, Inc. [DHIL] is up 44.46% over the past day.
Buy
100
WRBY alert for Dec 11
Warby Parker, Inc. [WRBY] is up 2.23% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
